It finally moves us away from the old 'one size fits all' approach
In a quiet but consequential shift in how medicine understands cancer, the NHS has approved olaparib — a drug that does not fight tumours broadly, but seeks them out by their genetic signature. For the roughly 900 patients each year in England whose breast or prostate cancers are driven by faulty BRCA genes, this approval marks the arrival of precision where there was once only probability. It is a reminder that within the vast, frightening category of 'cancer' lie many distinct diseases — and that naming them more precisely is the first step toward treating them more humanely.
- For patients carrying BRCA mutations, cancer has long meant facing a disease that medicine could fight but not yet target — olaparib changes that calculus directly.
- The drug works by cutting off a cancer cell's ability to repair itself, forcing it toward death rather than proliferation — a mechanism as elegant as it is consequential.
- Breast cancer patients face a mortality risk reduced by a third; men with advanced prostate cancer gain roughly six months of survival — numbers that are modest in the abstract and immense in a life.
- The NHS has secured a commercial agreement with AstraZeneca that will extend olaparib's reach across six cancer types, eventually treating up to 1,500 patients annually.
- Patients and advocates are welcoming the approval with relief tempered by realism — knowing that one breakthrough, however significant, does not end the wider struggle.
The NHS has approved olaparib — sold as Lynparza — for cancer patients carrying mutations in the BRCA1 or BRCA2 genes, the same genetic variants that entered public consciousness when Angelina Jolie underwent a preventative mastectomy a decade ago. The drug works by blocking PARP, a molecule that allows cancer cells to repair their damaged DNA. Without it, those cells cannot survive. For breast cancer patients, this translates to roughly a third reduction in mortality risk and a lower chance of recurrence. For men with advanced prostate cancer, it extends survival by approximately six months — a gain that carries enormous weight when the alternative is progression toward incurable disease.
Around 550 men with prostate cancer and 350 breast cancer patients in England will benefit each year, though a broader agreement with manufacturer AstraZeneca will eventually extend treatment to six cancer types, reaching up to 1,500 patients annually. BRCA mutations account for about five per cent of breast cancers — significant for those who carry them, and now, for the first time, a precise therapeutic target rather than simply a risk factor.
The human meaning of the approval is perhaps best understood through Joannah Kelly, a 44-year-old mother from South Croydon diagnosed with breast cancer days before giving birth to her second child in December 2020. After ten months of chemotherapy, a bilateral mastectomy, and radiotherapy, she took olaparib for a year to reduce her risk of recurrence. For her, the drug represented something between a shield and a second chance.
Advocates across both disease areas have welcomed the decision in similar terms. Breast Cancer Now called olaparib 'ground-breaking and potentially life-saving,' while Prostate Cancer UK described it as a 'landmark moment' — the first targeted treatment of its kind for the disease, and a meaningful step toward precision medicine tailored to genetic profile rather than generic, one-size-fits-all protocols. Kevin Webber, living with advanced prostate cancer since 2014, welcomed the news while noting the road ahead: 'We need to keep them coming to help men like me and their families.' The rollout for breast and prostate cancer patients begins immediately.
The NHS has approved olaparib, a drug that works by a mechanism most people have never heard of but that could reshape treatment for thousands of cancer patients carrying a genetic flaw they may not have known they had. The medication, marketed as Lynparza, targets tumours in people with mutations in the BRCA1 or BRCA2 genes—the same genetic variants that prompted Angelina Jolie to undergo a preventative double mastectomy a decade ago, bringing the condition into public consciousness.
The drug functions by blocking a molecule called PARP, which normally allows cancer cells to repair their damaged DNA. When PARP is blocked, those cells cannot fix themselves and die. For breast cancer patients, the effect is measurable: olaparib cuts the risk of dying by roughly a third and reduces the chance of the disease returning or worsening after initial treatment. For men with advanced prostate cancer, it extends survival by approximately six months—a gain that matters enormously when the alternative is progression toward incurable disease.
The approval will affect roughly 550 men per year in England with prostate cancer and around 350 breast cancer patients annually, though the NHS has negotiated a broader commercial agreement with manufacturer AstraZeneca that will eventually extend the treatment to six different cancer types, potentially reaching 1,500 patients yearly. BRCA mutations appear in about five per cent of breast cancers, making them a significant but not dominant factor in the disease's overall landscape. Yet for those who carry them, the mutation represents both a vulnerability and now, finally, a target.
Joannah Kelly, a 44-year-old mother of two from South Croydon, embodies what this approval means in practice. She was diagnosed with primary breast cancer in December 2020, just days before giving birth to her second child. Her treatment was intensive: ten months of chemotherapy, bilateral mastectomy, and radiotherapy. Beginning in November 2021, she then took olaparib for a year to reduce her risk of recurrence. For her and others like her, the drug represents something between a shield and a second chance—a way to push back against the possibility that cancer might return in a more aggressive, untreatable form.
Baroness Delyth Morgan, chief executive of Breast Cancer Now, called the approval "fantastic news," emphasizing that olaparib is "ground-breaking and potentially life-saving" for those with primary breast cancer who carry the mutation. The language reflects genuine significance: this is not a marginal improvement but a meaningful shift in what medicine can offer. For prostate cancer, the approval carries similar weight. Chiara De Biase of Prostate Cancer UK described it as a "landmark moment," noting that it represents the first targeted treatment of its kind for the disease and moves away from a generic, one-size-fits-all approach toward precision medicine tailored to genetic profile.
Kevin Webber, diagnosed with advanced prostate cancer in 2014, welcomed the approval as "fantastic," while acknowledging the broader struggle: "We need to keep them coming to help men like me and their families who are going through such tough times." His comment captures both the relief of having a new option and the awareness that for many, the battle remains difficult and uncertain.
Breast and prostate cancer together account for more than 100,000 diagnoses annually in the UK, making them the country's two most common malignancies. The NHS approval of olaparib for BRCA-mutated cases represents a recognition that not all cancers are identical, and that genetic testing and targeted treatment can offer better outcomes than blanket approaches. The rollout begins immediately for breast and prostate cancer patients; other cancer types covered by the agreement will follow.
Notable Quotes
For women like me, this ground-breaking drug has the potential to reduce the risk of cancer returning or progressing to incurable secondary breast cancer, and ultimately reduces the risk of dying from breast cancer.— Joannah Kelly, breast cancer patient
This is the first targeted treatment of its kind to be approved for the disease and it finally moves us away from the old 'one size fits all' approach to prostate cancer treatment.— Chiara De Biase, Prostate Cancer UK
The Hearth Conversation Another angle on the story
Why does a faulty gene in BRCA1 or BRCA2 make someone's cancer different enough to need a different drug?
Because the mutation leaves cancer cells dependent on a particular repair mechanism. When you block that mechanism, the cells can't survive. It's like finding the one lock a particular thief needs and changing it—suddenly they're trapped.
So this isn't a cure, then. It's more like buying time.
For advanced prostate cancer, yes—six months is real time, real life. For breast cancer after surgery, it's about preventing the return. That's different. It's not about extending a terminal illness; it's about stopping it from becoming terminal in the first place.
Why did it take until 2023 for this to reach the NHS if the drug has been around?
Cost, mostly. AstraZeneca and the NHS had to negotiate a price that worked for both. These drugs are expensive to develop and manufacture. The deal they struck makes it available now.
What happens to the 95 per cent of breast cancer patients without the mutation?
They get other treatments—chemotherapy, hormone therapy, immunotherapy depending on their cancer type. This drug is precise, which means it only helps people it's designed for. That's actually the point.
Does getting approved by the NHS change anything for patients who've already been taking it privately?
It means thousands more people can access it without paying out of pocket. For someone like Joannah Kelly, it means others won't have to fight as hard to get what she got.